Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 26Rituximab 17Etoposide 16Methotrexate 15Dexamethasone 15Cytarabine 15Vincristine 14Prednisone 11Doxorubicin 11Radiotherapy 10blinatumomab 8fludarabine 7Mercaptopurine 7Filgrastim 7Daunorubicin 7Asparaginase 7pegaspargase 6Granulocyte Colony-Stimulating Factor 6Methylprednisolone 5Drug Therapy 5Dasatinib 5venetoclax 4prednylidene 4etoposide phosphate 4deltacortene 4Trimethoprim, Sulfamethoxazole Drug Combination 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Busulfan 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Hizentra × Lymphoid × Clear all
NCT03211065 2021-04-19

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

Rochester General Hospital

Phase 2/3 Completed
16 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT03730129 2020-08-26

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

Rochester General Hospital

Phase 2/3 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡